Read about TAF, the components & mechanism of action of BIKTARVY® (bictegravir, emtricitabine, tenofovir alafenamide). Read full Prescribing Info, including BOXED WARNING.

Bictegravir/emtricitabine/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. [6]

2016年10月20日 · Bictegravir is used in combination with tenofovir alafenamide and emtricitabine to treat human immunodeficiency virus-1 (HIV-1) infection in patients weighing at least 14 kg. 8, 9 In the US, it may be used in treatment-naive patients.

BIKTARVY is a three-drug fixed dose combination product containing bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF). The recommended dosage of BIKTARVY is one tablet containing 50 mg of BIC, 200 mg of FTC, and 25 mg of TAF taken orally once daily with or without food in [see Dosage and Administration (2.4)]:

Learn about the importance of rapid ART initiation and its role in linkage to care and achieving viral suppression. Review data on BIKTARVY in treatment-naïve adults with HIV, including additional data on adherence and safety. Resistance is …

BIKTARVY is a three-drug fixed dose combination product containing 50 mg of BIC, 200 mg of FTC, and 25 mg of TAF. Prior to or when initiating BIKTARVY, test for hepatitis B virus infection.

BIKTARVY (bictegravir/emtricitabine/tenofovir alafenamide) is indicated as a complete regimen for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and pediatric patients weighing ≥ 25 kg with no known substitution associated with resistance to the individual

BIKTARVY® is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.

Biktarvy is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg without present or past evidence of viral resistance to the integrase inhibitor …

2018年2月19日 · The bictegravir contained in Biktarvy ® is an integrase strand transfer inhibitor that prevents the replication of the HIV 1 virus by blocking HIV-1 integrase, an enzyme required for replication of HIV virus. It also blocks the formation and propagation of HIV-1 provirus.